Positioning SGLT2 inhibitors/ incretin-based therapies in the treatment algorithm

Medicine and Dentistry

• Combination Therapy 100%
• Sodium Glucose Cotransporter 2 Inhibitor 66%
• Incretin 50%
• Therapeutic Procedure 50%
• Maturity Onset Diabetes of the Young 33%
• Adverse Event 33%
• Glucagon-Like Peptide-1 Agonist 33%
• Cardiovascular System 16%
• Diabetes 16%
• Hypoglycemia 16%
• Cell Function 16%
• Blood Pressure 16%
• Insulin Sensitivity 16%
• Pancreatitis 16%
• Genital Tract Infection 16%
• Health Care Cost 16%
• Dipeptidyl Peptidase-4 Inhibitor 16%
• Nausea 16%
• Diabetic Ketoacidosis 16%
• Drug 16%
• Chemotherapeutic Agent 16%
• Empagliflozin 16%
• Patient 16%